Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aradigm and CyDex have entered into a two-year collaboration agreement for the development and commercialization of combination products containing inhaled corticosteroids, anticholinergics and beta-2 agonists for the treatment of asthma and chronic obstructive pulmonary diseases.
Subscribe to our email newsletter
Under the terms of the agreement, the costs of the collaboration projects will be borne 60% by Aradigm and 40% by CyDex, with third-party licensing and sales revenues to be shared in the same ratio.
“There is a lot of interest in inhalation products containing a combination of drugs as these have proven to be very popular with millions of asthma and COPD patients,” said Igor Gonda, Aradigm's president and CEO. “We are pleased to be working with CyDex – a company with an excellent track record of developing and partnering innovative pharmaceutical products.”